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 Background The risk relevance of the P81S von Hippel-Lindau (VHL) gene hotspot mutation identified in clear cell renal cell carci-
noma from individuals exposed occupationally to trichloroethylene (TCE) is not known. VHL mutations in hereditary 
VHL syndrome strongly correlate with phenotypic associations, but specific sporadic mutations in VHL that uniquely 
alter its protein function may provide a selective growth advantage for somatic cells harboring these mutations.
 Methods VHL deficient (Vhl-/-) mouse embryonic stem cells were generated that stably express wild-type, P81S, or R167Q 
human VHL protein. Under hypoxic conditions, cell lines were examined for hypoxia-inducible transcription fac-
tor family (HIF) stabilization and E3-ubiquitin ligase complex interactions. In vivo, teratomas were examined 
for tumor size, proliferation, apoptosis, and immunohistochemistry and subjected to gene expression analysis. 
Wild-type, R167Q, and P81S VHL-expressing teratomas were also exposed to 5 Gy ionizing radiation to quantify 
apoptotic response. Proliferation and apoptosis and teratoma growth were analyzed by either Student t test or 
analysis of variance with Bonferroni correction. All statistical tests were two-sided.
 Results The P81S VHL mutation produces deregulation of HIF factors in cell culture but exhibits a growth advantage in the 
tumor microenvironment, in part because of suppression of apoptosis (P81S mean = 0.9%, 95% confidence inter-
val = 0.6 to 1.2%; WT mean = 7.6%; 95% confidence interval = 6.4 to 8.8%; P < .001) coupled with sustained prolifera-
tion. Transcriptional analysis of P81S teratomas revealed the induction of metabolic pathways, antiapoptotic genes, 
and global suppression of key DNA damage response genes not observed in VHL wild-type or R167Q mutants. In 
vivo irradiation exposure showed that P81S mutant is resistant to ionizing radiation–induced apoptosis.
 Conclusions The TCE-associated P81S VHL mutation can initiate a unique adaptive response required for selective tumor 
growth through pleiotropic effects on metabolic diversification, apoptosis suppression, and alteration of the DNA 
damage response.
  J Natl Cancer Inst;2013;105:1355–1364
Epidemiological studies have linked exposure to trichloroethylene 
(TCE), an organic solvent classified as a group 1 carcinogen and recog-
nized contaminant in groundwater, with increased incidences of clear 
cell renal cell carcinoma (ccRCC). A tumor-specific somatic C454T 
missense mutation in the von Hippel-Lindau tumor suppressor gene 
(VHL) has been linked with TCE-associated ccRCC cases (1,2). This 
mutation results in a single amino acid change from proline to serine 
at codon 81 of the VHL protein (P81S) and is observed in more than 
39% of TCE-exposed individuals who developed ccRCC (1).
The VHL tumor suppressor functions as a redox sensor, controlling 
stability of the hypoxia-inducible transcription factor family (HIFs). 
VHL forms a complex with Elongin B (TCEB2), Elongin C (TCEB1), 
Ringbox1 (RBX1), and Cullin2 (CUL2) to form an E3 ubiquitin ligase 
complex (VBC complex) (3). Under normal oxygen conditions, oxygen-
dependent prolyl-hydroxylase (PHD) enzymes hydroxylate HIF 
proteins at two specific proline residues that are recognized by VHL, 
and the VBC complex then polyubiquitinates HIF for degradation 
by the 26S proteasome (4). Cancer-associated missense mutations in 
VHL disrupt its function in the E3 ubiquitin ligase complex, resulting 
in variable deregulation of HIF factors (5,6). Structural models of 
molecular interactions between VHL and TCEB1 showed codons 81 
and 82 of VHL are direct TCEB1 binding sites, suggesting that the 
P81S mutation associated with TCE exposure could destabilize the 
VBC complex and result in HIF-mediated transcriptional activation 
of hypoxia response targets (7).
The HIF family members (HIF1A and HIF2A) play a central 
role in metabolic reprogramming observed in human renal tumors, 
which is thought to provide a selective survival advantage in chang-
ing microenvironments by modifying energy use during periods 
of hypoxic and glycolytic stress (8). This diversification of energy 
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sources through increased glycolysis (the Warburg Effect) (9), fatty 
acid oxidation (10,11), and glutaminolysis (12–14) can promote cell 
proliferation and, in some cases, resistance to chemotherapeutic-
induced apoptosis (15). HIF activation and metabolic changes have 
also been implicated as a result of Ataxia Telangiectasia Mutated 
(ATM) activation, a protein kinase involved in the response to 
DNA damage (16,17). Although HIF activation suggests a possible 
link between ATM-mediated DNA damage response and VHL, 
this has not been previously detected.
In this study, the TCE-associated P81S VHL mutation was 
modeled and its activity compared with cells expressing normal 
VHL and the hotspot R167Q VHL mutant that was previously 
shown to dysregulate both HIF factors in graded fashion (5,6,18). 
The results show that the unique TCE-associated VHL mutation 
has pleiotropic effects that selectively influence the tumor behavior 
in a mutation-specific manner, providing a selective growth advan-
tage through metabolic diversification, apoptosis suppression, and 
alteration of the DNA damage response.
Methods
Site-Directed Mutagenesis
Vhl-/- embryonic stem (ES) cells were generated and propagated as 
previously described (18). Site-directed mutagenesis of the pST-HA-
VHL parental construct to mutate the proline at nucleotide position 
454 to a serine residue was performed using the QuikChange II XL 
site-directed mutagenesis kit (Stratagene, La Jolla, CA). Primer sets 
used were (specific base changes underlined) 5′-GCAATCGCAGTT
CGCGCGTCG-3′ and 5′-CGACGCGCGAACTGCGATTGC-3′. 
ES clones were selected using media containing 200 µM hygromy-
cin and were tested for hemaggulutinin (HA)–VHL expression by 
Western blot. Immunoprecipitation experiments were performed 
using the Pierce Mammalian HA-tag Co-IP kit (Pierce, Rockford, 
IL) as previously described (5).
Hypoxia Treatments
ES cell lines were plated on gelatin-coated cell culture dishes and 
exposed to 100 uM cobalt (II) chloride (CoCl2), a hypoxia mimetic, 
for 16 hours, whereas normoxic controls received media replace-
ment only. After treatment, cell pellets were isolated and snap fro-
zen for RNA isolation or Western blot analysis. Western blots were 
performed as previously described (5), and blot densitometry was 
performed using ImageJ software (http://imagej.nih.gov/ij/).
In Vivo Teratomas and Reverse-Transcription Polymerase 
Chain Reaction (RT-PCR)
Female Foxn1nu/nu mice aged 6 to 8 weeks were injected subcutane-
ously in bilateral flanks with 1 × 106 cells of each HA-VHL cell line, 
for a total of eight tumors (two per mouse) per wild-type (WT) 
and R167Q clone and 16 total for two independent P81S clones. 
Tumor growth was measured three times a week using calipers 
until tumors reached a maximum dimension of 1 cm. To examine 
tumor hypoxia, mice were injected with 60 mg/kg Hypoxyprobe-1 
(Natural Pharmacia International, Belmont, MA) 1 hour before 
they were killed. Tumors were excised and either flash frozen or 
formalin-fixed and paraffin-embedded. Total RNA from teratomas 
and ES cell pellets was isolated using RNAeasy Mini Kits (Qiagen, 
Valencia, CA), followed by cDNA preparation from 10 to 40 ng/
uL RNA using Applied Biosystems (Carlsbad, CA) cDNA Archive 
kit. For quantitative RT-PCR, primer/probe sets were purchased 
from Applied Biosystems. Data were normalized to loading con-
trol beta-glucuronidase or beta-actin, and results were calculated 
using the ΔΔCt method (19). Animal studies were approved by the 
Institutional Animal Care and Use Committee.
Radiation Exposure
Teratomas were grown as above, and mice were placed into a 
Gammacell 40 Exactor CS-137 irradiator (Best Theratronics, 
Ottawa, Ontario) with a radiation source of 1800 ± 15% Curies (Ci) 
cesium 137 and delivered a single dose of 5 Grays (Gy), whereas 
others received no treatment. Mice were killed 4 and 24 hours after 
exposure, and tumors were formalin fixed and paraffin embedded.
Immunohistochemistry and Microarray Analysis
Immunohistochemistry was performed on 5-μm paraffin-embedded 
sections using the following primary antibodies: anti-Ki67 and 
anti-cyclin D1 (Abcam, Cambridge, MA); anti-hypoxyprobe-1 
(Hypoxyprobe, Inc); and anti-phosphorylated ATM at Serine 1981 
(Sigma-Aldrich, St. Louis, MO). Avidin-biotin complex (ABC) 
enhancement kit and 3,3′-diaminobenzidine (DAB) detection 
reagent (Vector Laboratories, Burlingame, CA) was used for vis-
ualization. Apoptosis staining was performed using the ApopTag 
In Situ Apoptosis Detection Kit (Millipore, Billerica, MA). Slides 
were counterstained with 2-(4-amidinophenyl)-1H-indole-6-car-
boxamidine (DAPI) to facilitate cell counts. Quantitative analysis 
was performed using BIOQUANT software (BIOQUANT Image 
Analysis, San Diego, CA) by averaging percentage of positively 
stained cells to total cells within six random fields at ×200 magni-
fication. Microarray experiments were performed using GeneChip 
Mouse ST Gene 1.1 whole genome arrays (Affymetrix, Santa 
Clara, CA) at the University of North Carolina Genomics Core 
Facility. The data have been deposited in the National Center for 
Biotechnology Information’s Gene Expression Omnibus (20) and 
are accessible through accession number GSE37464.
Pathway and Statistical Analysis
Gene expression data (CEL files) were analyzed using Partek 
Genomic Suite, version 6.5 (Partek Inc, St. Louis, MO). Gene 
expression data were normalized by robust multiarray analysis, 
and analysis of variance (ANOVA) was performed using Partek 
software. Differentially expressed genes were identified between 
classes using the nonparametric rank-product method (P < .05 and 
P < .01), and log2 expression values for each gene were generated. 
Canonical pathway analysis was generated through the use of Ingenuity 
Pathways Analysis (Ingenuity Systems, Redwood City, CA). Canonical 
pathway analysis was measured as a ratio of the number of genes 
from the dataset that map to a pathway divided by the total number 
of genes that map to the canonical pathway. Fisher exact test was used 
to calculate a P value. Significance for real-time RT-PCR experiments, 
quantification of proliferation and apoptosis, and teratoma growth was 
determined by either Student t test for comparison of two groups or 
ANOVA with Bonferroni correction for significance comparing VHL 
mutants with WT VHL. All statistical tests were two-sided.
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results
To test whether the P81S VHL mutant disrupts VBC complex 
interactions, extracts from VHL deficient (Vhl-/-) murine ES cells 
expressing HA-tagged WT, P81S, or R167Q human VHL pro-
tein were immunoprecipitated with an antibody directed toward 
the HA tag and examined for coimmunoprecipitation with VBC 
complex members. WT VHL cells retained their interaction with 
all VBC complex members, However, extracts from both P81S and 
R167Q mutants failed to coprecipitate with TCEB1 (Elongin C 
[Figure 1A]) but did retain interaction with CUL2 (Culin 2), RBX1 
(Ringbox 1), and TCEB2 (Elongin B) (Figure 1, A and B).
Disruption of the VBC complex would result in loss of HIF 
targeting and lead to stabilization of HIF during normal oxygen 
conditions. To evaluate HIF levels, two independent clones of the 
P81S mutant, as well as Vhl-/-, WT, and R167Q cell lines, were 
analyzed for HIF1A protein expression after 16 hours of growth 
in the presence of normal oxygen (21% O2) or hypoxia mimetic 
CoCl2 (Figure  1C). HIF1A was stabilized under normoxic con-
ditions with no further increase during treatment with CoCl2 in 
Vhl-/- cells, whereas HIF1A protein was minimal in lysates from 
WT VHL cells in normoxic conditions, suggesting degradation of 
HIF by the VBC complex. In contrast, HIF1A remained partially 
stabilized in P81S and R167Q mutant cells during normoxia, con-
sistent with the inability of VHL mutants to support normal VBC 
complex function.
To verify that stabilized HIF1A protein results in functional 
activity, transcriptional activation of HIF-targeted genes was 
quantified by RT-PCR using mRNA isolated from P81S, WT, 
R167Q, and Vhl-/- cell lines (Figure 1D). Whereas R167Q showed 
greater than twofold excess transcript levels compared with WT 
for HIF1A target genes EglN3 and Vegf during normoxia with fur-
ther induction during hypoxia, Glut1 was regulated normally in 
these conditions. In contrast, P81S displayed a normoxic excess of 
the glucose transporter Glut1 but normal regulation of the targets 
EglN3 and Vegf, suggesting differential HIF1A targeting occurs 
between the R167Q and P81S VHL mutants. The most notable dif-
ference observed between the mutants and the Vhl-deficient cells 
was in the degree to which HIF1A was stabilized. Both P81S and 
R167Q mutants preserved the ability of hypoxia to induce HIF1A 
beyond basal levels, suggesting that neither mutant produced maxi-
mal stabilization of HIF.
During a physiological response to hypoxia, HIF factors are 
stabilized to activate the expression of hypoxia response element 
(HRE)-dependent genes, which represent a wide range of physi-
ological processes, including angiogenesis, energy metabolism, 
glycolysis, and cell cycle (4,21). In addition to physiological pro-
cesses, another major limitation of examining cell lines in vitro is 
the inability to examine deregulated HIF2 transcriptional activity 
(18,21). Therefore, to study the phenotypic consequences under 
conditions mimicking the tumor environment, ES cell lines were 
subcutaneously injected in the flank region of nude mice to evalu-
ate in vivo teratocarcinoma growth. The most striking effect was 
a threefold increase in P81S teratoma volume relative to WT and 
a sixfold increase over R167Q teratomas (Figure  2, A–C). Vhl-
/- cells were nearly completely impaired in supporting teratoma 
growth (data not shown). The relative proliferation index between 
WT and P81S teratomas was not statistically significantly differ-
ent (Figure 2, E and F), suggesting that a proliferative advantage 
was not the primary reason for increased teratoma volume. Rather, 
results showed a statistically significant reduction in the percentage 
of apoptotic cells in P81S compared with both WT and R167Q 
(P81S mean  =  0.9%, 95% confidence interval [CI]  =  0.6% to 
1.2% vs WT mean = 7.6, 95% confidence interval = 6.4% - 8.8%; 
P < .001) (Figure 2, G and H).
Analysis of teratoma sections revealed disorganized vasculariza-
tion in the R167Q teratomas consistent with sustained HIF response 
(Figure 2D). P81S teratomas, in contrast, displayed an increase in 
microvessel density but overall a pattern more consistent with WT 
teratomas. Because tumor vasculature can modify oxygen delivery 
and apoptotic response, hypoxia was analyzed using a hypoxia tracer 
(Figure 2I). The R167Q mutant demonstrated global reduction in 
regional hypoxia, whereas no differences were observed between 
WT and P81S, suggesting that the growth advantage associated with 
the P81S mutation does not result from an angiogenic response.
Because analysis of in vitro grown cells suggested VHL mutants 
show differential HIF1A regulation (Figure 1D), expression of the 
HIF2A target gene Cyclin D1 (CCDN1) was analyzed. CCDN1 
was overexpressed specifically in P81S teratomas (Figure 2J), fur-
ther suggesting differential HIF isoform deregulation between the 
two mutants may be driving phenotypic differences. Because of the 
numerous HIF targets as well as stress response genes that may 
contribute to phenotypic differences, gene expression profiling of 
RNA from VHL teratomas was used to elucidate molecular path-
ways underlying the unique P81S adaptive response.
Unsupervised hierarchical clustering of whole genome microar-
ray data showed independent clustering of replicate P81S terato-
mas distinct from WT and R167Q teratomas. Analysis of variance 
of all genes revealed that samples segregated based on genotype, 
with the WT and R167Q teratomas appearing more similar to 
each other than to the P81S teratomas, with 2622 genes differen-
tially expressed among the three genotypes (Figure 3A). RT-PCR 
validation of select differentially expressed genes was performed 
(Figure 4). Pathway analysis of gene sets differentially expressed in 
WT vs both mutant genotypes revealed several functional differ-
ences consistent with VHL-associated phenotypes (Figure 5).
Biological pathway analysis on all statistically significantly 
expressed genes (P < .05) identified molecular pathways 
uniquely expressed in the P81S mutant, including modulation 
of HIF-specific targets, indicative of redirected HIF targeting 
(Figure 3B). P81S teratomas also had increased expression of genes 
associated with energy metabolism, including fatty acid oxidation, 
mitochondrial biogenesis, and glutaminolysis, suggestive of the 
use of glutamine-derived α-ketogluterate for energy production. 
Mitochondrial respiration has been shown to be essential for tumor 
proliferation (12,13), suggesting that alternative use of lipids and 
glutamate as a source of acetyl coenzyme A may be an important 
adaptive mechanism in P81S teratomas. Mitochondrial metabolism 
increases the production of reactive oxygen species and, as a 
consequence, induces genes associated with antioxidant activity 
(22,23), which was also observed in the P81S teratomas.
Cancer cells often upregulate an intrinsic stress response system 
during tumor hypoxia or oxidative stress to avoid apoptotic signals 
(24,25). In agreement, the antiapoptotic gene Bcl2 was upregulated 
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Figure 1. VHL mutants partially abrogate VBC complex interactions and 
allow hypoxia-inducible transcription factor family (HIF) transactiva-
tion during normal oxygen conditions. Immunoprecipitation of stably 
transfected Vhl−/− mouse embryonic stem (ES) cell lines expressing 
hemaggulutinin (HA)–tagged wild-type (WT), two independent clones 
of P81S mutant or R167Q mutant VHL under normoxic conditions. Cells 
were lysed under nondenaturing conditions and subject to coimmu-
noprecipitation with an antibody against the HA tag. Anti-HA precipi-
tated products were probed for pull-down of HA-VHL with VBC complex 
members Ringbox 1 and Elongin C (A) and Cullin 2 and Elongin B (B). 
C) Immunoblot of HIF1A stabilization during normoxic and hypoxic 
conditions. Whole-cell protein extracts were prepared from stably trans-
fected Vhl−/− mouse ES cells expressing WT, P81S mutants, or R167Q 
mutant HA-VHL under normoxic and hypoxic conditions induced by 
100 μM cobalt (II) chloride (CoCl2). Western blot shows HIF1A. * denotes 
HIF1A protein as the upper band. Beta-tubulin was loading control. 
Densitometric analysis using ImageJ software of HIF1A/tubulin is 
shown with relative intensity to normoxic WT. D) Expression of HIF1A 
transcriptional target genes in VHL ES cell lines grown under normoxic 
and hypoxic conditions for 24 hours. The expression was examined by 
reverse-transcription polymerase chain reaction. Beta-actin was used 
as the loading control. Data are mean fold expression over normoxic 
WT ± 95% confidence intervals of three independent cultures from two 
independent experiments. P values were calculated using two-sided 
Student t test. *P ≤ .01 relative to normoxic WT. #P ≤ 0.04 relative to 
normoxic treatment of same cell line. Vegf  =  vascular endothelial 
growth factor alpha; Glut1 = glucose transporter 1; Egln3 = elongin 3; IP, 
immunoprecipitation; WB, western blot.
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Figure 2. The P81S VHL mutant displays a marked growth advantage and 
apoptotic resistance despite hypoxic tumor microenvironment. A) In vivo 
teratoma assay of VHL embryonic stem (ES) cell clones. Stably transfected 
Vhl−/− mouse ES cells expressing wild-type (WT), two independent clones 
of P81S or R167Q VHL were injected subcutaneously into the flank region 
of nude mice and allowed to grow for 4 weeks. Mice were killed, and tera-
tomas were removed and photographed. B) Gross images of ES cell tera-
tomas bisected to visualize blood vessels and placed next to a standard 
metric ruler for size reference. C) Tumor volume was measured weekly 
using calipers. Data are mean tumor volume ± 95% confidence interval of 
eight individual tumors per VHL clone, including two P81S clones. P values 
were calculated at 4 weeks using analysis of variance with Bonferroni cor-
rection. **P ≤ .001 comparing P81S and R167Q with WT. D) Hematoxylin 
and eosin (H&E) staining of WT, P81S, and R167Q VHL teratoma sec-
tions show areas of differentiation and neovascularization, as indicated 
by black arrows. Scale bars = 100 µm. E) Immunohistochemistry for the 
proliferation marker Ki67 was performed on paraffin-embedded 5-μM sec-
tions showing positively stained cells in brown. Scale bars = 100 µm. F) 
Quantification of proliferation was performed by averaging percentage of 
positively stained cells to total cells within six random fields at ×200 mag-
nification. Data show mean percentage ± 95% confidence interval of eight 
individual tumors per VHL clone. Statistical significance was determined 
by analysis of variance with Bonferroni correction. *P ≤ .008 comparing 
P81S and R167Q with WT. G) Immunohistochemical analysis of apopto-
sis using a modified terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL-FITC) assay with fluorescein isothiocyanate detection on 
paraffin-embedded 5-μM sections. Red: DAPI nuclear stain; Green: cells 
positive for apoptosis. Scale bars = 100 µm. H) Quantification of apopto-
sis was performed by averaging percentage of positively stained cells to 
total cells within six random fields at ×200 magnification. Data show mean 
percentage ± 95% confidence interval of eight individual tumors per VHL 
clone. Statistical significance was determined by analysis of variance with 
Bonferroni correction. **P ≤ .001 comparing P81S and R167Q with WT. 
I) Immunohistochemical analysis of tumor sections for hypoxic regions 
using hypoxyprobe-1. Black arrows denote areas positively stained for 
hypoxia. Scale bars = 500 µm. J) Immunohistochemistry for HIF2A target, 
cyclin D1, was performed on paraffin-embedded 5-μM sections showing 
increased cyclin D1 expression in P81S teratomas. Scale bars = 100 µm.
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and the proapoptotic genes Trp53, Bax, Bnip3, and Tnfrsf10 were 
downregulated only in P81S teratomas, supporting the decreased 
apoptotic index (Figure  2H). Conversely, expression of Atm, a 
central regulator of the DNA damage response and HIF activa-
tion, was suppressed exclusively in the P81S mutant, as were other 
factors involved in the recognition and response to DNA dam-
age (Figure 3C). This novel finding suggests that there may be a 
previously unrecognized direct relationship between Vhl and Atm 
expression, indicating that suppression of apoptosis within the 
tumor microenvironment in the P81S mutant may be due to a loss 
of the DNA damage recognition response.
If metabolic reprogramming and suppression of Atm expres-
sion leads to attenuation of the P81S mutant apoptotic response, 
then exposure to a direct-acting exogenous stressor such as 
radiation should result in decreased Atm phosphorylation and 
suppression of apoptosis. To test this, teratomas were exposed 
in vivo to ionizing radiation, revealing a statistically significant 
reduction in phosphorylated Atm in P81S compared with WT 
teratomas (mean for P81S = 25.8% vs 54.0% in WT and 47.5% 
in R167Q; difference = 28.2%; 95% CI = 14.7% to 36.9%; P < 
.001) (Figure  6, A and B), consistent with loss of Atm expres-
sion in P81S teratomas (Figure  3G). A  statistically significant 
decrease in apoptosis was also observed in P81S VHL teratomas 
(mean for P81S = 5.9% vs 55.8% in WT and 51.2% in R167Q; 
difference = 49.9%; 95% CI = 4.7% to 7.1%, P < .001) (Figure 6, 
C and D).
Figure  3. Transcriptional profiling of teratomas reveals altered meta-
bolic reprogramming, HIF2A transcriptional target activation, and sup-
pression of both the DNA damage and apoptotic response in P81S 
mutants. A) Hierarchical clustering of differentially expressed genes 
from embryonic stem ES) cell teratomas. Stably transfected Vhl−/− 
mouse ES cells expressing wild-type (WT), P81S (both clones rep-
resented), or R167Q VHL were injected subcutaneously into the flank 
region of nude mice and allowed to grow for 4 weeks. RNA was isolated 
from three to four independent tumors from each genotype and used 
to perform microarray analysis using the Affymetrix Mouse Gene ST 
1.1 whole genome array. Differentially expressed genes between VHL 
genotypes were determined using Partek Genomics Suite. Statistical 
significance was determined by analysis of variance; P ≤ .001. The gene 
list of 2622 genes was then clustered unsupervised by expression. 
Log2 expression color scale: Red: upregulated; Blue: downregulated. 
B) List of genes differentially regulated exclusively in P81S teratomas. 
Biological pathway analysis was performed on genes that were differen-
tially regulated in P81S but not in WT or R167Q teratomas. Differentially 
expressed genes between the apoptosis phenotypes were determined 
using Partek Genomics Suite. Statistical significance and fold change 
in expression (antiapoptotic/apoptotic phenotype) was determined by 
two-sided Student t test, P ≤ .05. C) Heat-map showing downregulation 
of DNA damage response genes in the P81S mutant teratomas com-
pared with WT VHL and R167Q VHL teratomas. Differentially expressed 
genes were determined Partek Genomics Suite. Statistical significance 
was determined by analysis of variance, P ≤ .05. Atm = ataxia telengec-
tasia mutated; Brca1 = breast cancer associated 1; Chek1 = checkpoint 
kinase 1; Chek2 = checkpoint kinase 2; Mre11a = meiotic recombination 
11 homolog A; Rad50 = Rad50 homolog A; Rad51 = Rad51 homolog A; 
Xrcc5 = x-ray cross-complimenting 5.
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Discussion
The data presented herein demonstrate that the TCE-associated 
P81S VHL mutation can dramatically alter growth properties of 
cells, providing a survival advantage even under environmental 
stress conditions. Although the mechanism creating this high-
frequency somatic mutation is uncertain (1), functional analysis of 
this unique TCE-associated mutation highlights three important 
concepts for VHL biology and renal tumorigenesis.
First, although it has been recognized for some time that VHL 
mutations could differentially deploy HIF1A and HIF2A, as well 
as redirect the transcriptional response, results in this study show 
that individual mutations such as P81S have effects that are only 
revealed in the complex in vivo tumor growth environment. It is 
in the teratoma model that the P81S mutation uniquely displayed 
potential to traverse tumor initiation and progression, producing 
highly aggressive in vivo growth. Strikingly, this mutation failed 
to support an increased angiogenic phenotype that has been char-
acteristic of ccRCC-associated tumors (26) but displayed tissue 
level hypoxia, which has been characteristically absent in VHL-
deficient and other VHL mutation models (6,18,27). Thus, there 
is the opportunity with the P81S somatic mutation to produce 
Figure  4. Quantitative reverse-transcription polymerase chain reaction 
(RT-PCR) validation of differentially expressed genes identified from whole 
genome arrays on VHL teratomas. Stably transfected Vhl−/− mouse embry-
onic stem (ES) cells expressing wild-type (WT), P81S (both clones repre-
sented), or R167Q VHL were injected subcutaneously into the flank region of 
nude mice and allowed to grow for 4 weeks. RNA was isolated from three to 
four independent tumors from each genotype and used to perform quantita-
tive RT-PCR analysis on select genes found to be differentially expressed in 
whole genome microarray experiments by Partek Genomics Suite. Statistical 
significance was determined by analysis of variance, *P ≤ 0.02. Atm = ataxia 
telengectasia mutated; Brca1 = breast cancer associated 1; Ppargc1a = per-
oxisome proliferator alpha receptor gamma isoform c1 alpha; Trp53 = trans-
formation-related protein p53; Vegfa = vascular endothelial growth factor.
Figure  5. Transcriptional profiling of teratomas comparing wild-type 
(WT) vs mutant VHL. A) Venn diagram of differentially expressed genes 
from embryonic stem (ES) cell teratomas. Stably transfected Vhl−/− mouse 
ES cells expressing WT, P81S (both clones represented), or R167Q VHL 
were injected subcutaneously into the flank region of nude mice and 
allowed to grow for 4 weeks. RNA was isolated from three to four inde-
pendent tumors from each genotype and used to perform microarray 
analysis using the Affymetrix Mouse Gene ST 1.1 whole genome array. 
Differentially expressed genes between VHL genotypes were determined 
using Partek Genomics Suite. Statistical significance was determined by 
Student t test and analysis of variance, P ≤ .01. B) List of pathways dif-
ferentially regulated between both VHL mutants and the WT VHL terato-
mas. Biological pathway analysis was performed using Ingenuity Pathway 
Analysis on 1644 genes that were differentially regulated between WT and 
mutant VHL teratomas; 1065 genes were downregulated and 579 genes 
were upregulated in mutant VHL teratomas compared with WT. Canonical 
pathway analysis was measured as a ratio of the number of genes from 
the dataset that map to a pathway divided by the total number of genes 










Differentially Expressed in Mutant vs WT VHL (n = 1644)
Pathways statistically significantly increased in mutant VHL genotypes (n = 579)




Decreased permeability transition of mitochondrial membrane 3.14E-04
Hypoxia-inducible factor signaling 1.82E-08
Pathways statistically significantly decreased in mutant VHL genotypes (n = 1065)
Molecular pathway name P value
Assembly of RNA Polymerase II complex 1.91E-04
Estrogen receptor signaling 1.14E-02
Protein ubiquitination signaling 3.09E-02
Nucleotide excision repair pathway 3.96E-02
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phenotypes that are highly influenced by the hypoxic microenvi-
ronment of tumor growth.
Second, the P81S mutation is linked to mechanisms that sup-
port tumorigenesis by promoting pathways different from the 
classic glucose metabolism and exuberant angiogenesis that typi-
fies ccRCC (8,26,28,29). In particular, these data demonstrate that 
VHL-regulated factors can dramatically alter growth properties 
and are associated with an altered metabolic program. The P81S 
response signature indicates increased mitochondrial biogenesis, 
fatty acid oxidation and glutamine synthesis, suggesting that an 
early step in metabolic reprogramming may be a change in carbon 
source diversification. In addition to glucose-derived pyruvate, the 
use of lipids and glutamine provides additional sources of carbon 
for the trichloroacetic acid (TCA) cycle in the form of acetyl coen-
zyme A and α-ketoglutarate (11–13). The requirement of energy 
source diversification is supported by previous studies that have 
shown that pharmacological inhibition of fatty acid oxidation abol-
ished cellular proliferation and sensitized cells to apoptosis (30) 
and, further, inhibition of glutaminolysis during hypoxia resulted 
in loss of cell viability (12). This diversification facilitates “meta-
bolic switching” within the tumor microenvironment during states 
of environmental stress to support a continuous yield of reducing 
equivalents for oxidative phosphorylation, aiding tumor survival.
Third and finally, P81S teratomas gained a growth advantage 
resulting from apoptotic resistance rather than enhanced pro-
liferation, raising the threshold of sensitivity to endogenous and 
exogenous stressors. Transcriptomic analysis suggested that a key 
component of this growth advantage is a disabling of the DNA 
damage response through suppression of DNA damage recogni-
tion and repair proteins. The loss of these genoprotective mecha-
nisms was associated with decreased phosphorylation of Atm 4 
hours after irradiation and a blunted apoptotic response at 24 hours 
after irradiation. This highlights a previously uncharted intersec-
tion of VHL programming and the DNA damage response, which, 
in the case of the P81S mutation, produces a highly advantageous 
growth environment.
Functional analysis of the unique TCE-associated P81S VHL 
mutant supports a new model whereby the VBC complex is dis-
rupted and stabilizes HIF during normal oxygen conditions, thus 
priming tumor cells for adaptation when challenged by a hypoxic 
tumor microenvironment (Figure  7). To continue proliferation 
and avoid apoptotic stress signals, the P81S mutant likely initi-
ates an adaptive environmental stress response by pleiotropic 
effects. By modulating energy metabolism genes, upregulating 
radical scavenging antioxidant genes, and downregulating key 
DNA damage response and proapoptotic genes, the P81S mutant 
is able to suppress apoptotic signals and continue proliferating 
within a hypoxic microenvironment, even resisting irradiation-
induced apoptosis. These findings are relevant for understanding 
how mutations in VHL could promote tumorigenesis by driving 
metabolic diversification, demonstrating a class of VHL muta-
tions for which tumors may be inherently resistant to radiation 
and antiangiogenic therapies and which may require alternate 
targeting strategies.
Figure 6. P81S VHL mutant shows reduced phosphorylation of Ataxia 
Telangiectasia Mutated (ATM) and resistance to ionizing radiation–
induced apoptosis. In vivo irradiation of nude mice during teratoma 
assay of VHL embryonic stem (ES) cell clones. Stably transfected 
Vhl−/− mouse ES cells expressing WT, P81S, or R167Q VHL were 
injected subcutaneously into the flank region of nude mice and were 
allowed to grow to a maximum size of 1 cm. Mice were then exposed 
to a single dose of either 0 Gy or 5 Gy ionizing radiation and killed 
after 4 and 24 hours. Teratomas were removed and paraffin embed-
ded, and immunohistochemistry was performed on 5-μM sections. A) 
Sections were stained using a primary antibody against phosphoryl-
ated-ATM protein at serine 1891 and visualized using a fluorescently 
conjugated secondary antibody. Red: phosphorylated-ATM protein. 
B) Quantification of phosphorylated-ATM in teratomas 4 hours after 
a single dose of 5 Gy ionizing radiation. Data are mean percentage 
of phosphorylated-ATM protein ± 95% confidence interval of four 
random fields at ×100 magnification in three independent tumors 
per VHL clone. C) Sections were stained for apoptosis using a modi-
fied terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL-FITC) assay with fluorescein isothiocyanate detection. Green: 
cells positive for apoptosis. D) Quantification of apoptosis in terato-
mas 24 hours after a single dose of 5 Gy ionizing radiation. Data are 
mean percentage of apoptotic cells ± 95% confidence interval of five 
random fields at ×200 magnification in three independent tumors 
per VHL clone. P values were calculated using analysis of variance, 
**P ≤ .001. Scale bars = 200 µm.
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This study had some limitations. First, we used the in vivo tera-
toma assay to perform a comparative analysis of mouse embry-
onic stem cells expressing human gene variants, and although this 
system has successfully modeled several human VHL mutation- 
associated phenotypes (18), the tumor microenvironmental cues 
are endogenously derived. The selective growth pressure and 
response may be altered in a single mutated cell among surround-
ing terminally differentiated cells. Second, the metabolic repro-
gramming observed in transcriptional profiles of P81S VHL 
teratomas shows clear translational potential and is an exemplar 
of the metabolic changes that commonly occur in human renal 
tumors. Future studies should be aimed at the functional analysis 
of these metabolic alterations, including quantitative physiological 
measurements of mitochondrial function and fatty acid metabo-
lism. Third, the evaluation of the TCE exposure–associated 
P81S VHL mutation suggests a potential mechanism for tumor 
promotion and does not elucidate the mode of action for TCE 
exposure–associated VHL mutagenesis. There is a critical need 
for additional biologically based exposure models to examine the 
conditions necessary for exposure-induced renal carcinogenesis. 
Fourth, although VHL has several cellular functions, its modula-
tion of ATM-mediated DNA damage response suggests it plays a 
role in the DNA damage response network, and additional studies 
will be required to elucidate this newly identified relationship.
In summary, the TCE-associated somatic VHL mutation pre-
sents a high-risk allele for clonal expansion and highlights several 
new features of VHL-related tumorigenesis that are often over-
shadowed by effects on glycolysis and tumor angiogenesis, com-
monly associated with VHL loss. Although numerous reports have 
linked HIF activation to metabolic reprogramming (28,31), this is 
the first report connecting a particular VHL mutation to cellular 
metabolic regulation and ATM damage response and demonstrat-
ing that microenvironmental cues likely factor heavily on in vivo 
phenotypes.
Figure 7. Schematic of model proposing mechanism of altered stress 
response and apoptotic resistance of P81S VHL mutant. P81S VHL 
mutation allows hypoxia-inducible transcription factor family (HIF) 
stabilization and transcriptional activation during normal oxygen con-
ditions, creating a state of chronic “pseudo-hypoxic” signaling within 
the cell. HIF activation and transcriptional signaling in the presence of 
oxygen primes tumor cells for adaption when challenged by a hypoxic 
tumor microenvironment. The transcriptional data suggest that the 
initial step in metabolic reprogramming may be a change in carbon 
source diversification. In addition to glucose-derived pyruvate, the 
use of lipids and glutamine provides additional sources of carbon for 
the tricarboxylic acid cycle (TCA) cycle in the form of acetyl coenzyme 
A and α-ketoglutarate. This diversification would then facilitate “meta-
bolic switching” within the proliferative tumor microenvironment to 
support a continuous yield of reducing equivalents for oxidative phos-
phorylation. As a compensatory mechanism to prevent reactive oxy-
gen species (ROS)-induced damage, antioxidant genes are upregulated 
and proapoptotic genes are suppressed, along with the DNA damage 
response, resulting in an apoptotic-resistance phenotype secondary to 
changes in metabolism. Acox, acyl-Coenzyme A oxidase; Atm, ataxia 
telangiectasia mutated; Bcl2, b-cell lymphoma factor 2; Cat, catalase; 
Cpt1c, carnitine palmitoyltransferase; Cul2, cullin-2; Elgnb, elongin B; 
Eglnc, elongin C; FAO, fatty acid oxidation; Glul, glutamine synthase; 
Glut4, glucose transporter 4; Hif1, hypoxia-inducible factor isoform 1; 
Hif2, hypoxia-inducible factor isoform 2; HRE, hypoxia response ele-
ment; Ppargc, peroxisome proliferator alpha receptor gamma isoform 
c1 alpha; Prdx2, peroxiredoxin 2; Rbx1, ringbox 1; Sod2, mitochondrial 
superoxide dismutase.
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